Clinical trial

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

NCT05893381

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention [177Lu]Lu-PSMA I&T Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Stereotactic Radiotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-06-27

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

[177Lu]Lu-PSMA I&TDRUG

Stereotactic RadiotherapyRADIATION

Sponsors & collaborators

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05893381 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.